Cavinton improves cerebral perfusion hereby improving the oxygen supply of the brain.
In animal experiments, it enhances cerebral regeneration after experimental hypoxia.
Management of psychic and neurological symptoms (memory disorders, aphasia, opraxia, motor disorders, dizziness, headache) of cerebral circulatory disorders of various origin (postapoplectic, posttraumatic or sclerotic), vasovegetative symptoms of climax syndrome.
Hypertensive encephalopathy, intermittent vascular cerebral insufficiency, angiospastic cerebral states, cerebral endarteritis. It improves collateral circulation in ischaemic cerebral injuries and in advanced cerebral arteriosclerosis.
Ophthalmology: Macula degeneration due to the vascular first of all arteriosclerotic or angiospastic alteration of the retina and chorioidea, secondary glaucoma due to partial thrombosis or occlusion.
Otology: Vascular presbyacusis, certain toxic (iatrogenic) hearing impairments, vertigo of labyrinth origin.
1-2 tablets 3 times daily. Maintenance Dose: 1 tablet 3 times daily for a longer period of time.
This drug is contraindicated in pregnancy.
Slight hypotension, occasionally tachycardia, immature beats may occur at times. On long-term treatment, blood count is suggested to be performed.
No interactions of the tablets with other drugs were reported, therefore, it can be administered in combination.
N06BX18 - vinpocetine ; Belongs to the class of other psychostimulants and nootropics.